506 related articles for article (PubMed ID: 29157685)
41. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
Alsfouk A
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
[TBL] [Abstract][Full Text] [Related]
42. Bioorthogonal small molecule imaging agents allow single-cell imaging of MET.
Kim E; Yang KS; Weissleder R
PLoS One; 2013; 8(11):e81275. PubMed ID: 24265843
[TBL] [Abstract][Full Text] [Related]
43. O-linked triazolotriazines: potent and selective c-Met inhibitors.
Chen F; Wang Y; Ai J; Zhan Z; Lv Y; Liang Z; Luo C; Mei D; Geng M; Duan W
ChemMedChem; 2012 Jul; 7(7):1276-85. PubMed ID: 22539497
[TBL] [Abstract][Full Text] [Related]
44. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
[TBL] [Abstract][Full Text] [Related]
45. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
Tang Q; Wang L; Duan Y; Wang W; Huang S; Zhi J; Jia S; Zhu W; Wang P; Luo R; Zheng P
Eur J Med Chem; 2017 Jun; 133():97-106. PubMed ID: 28384549
[TBL] [Abstract][Full Text] [Related]
46. Safety and Tolerability of c-MET Inhibitors in Cancer.
Puccini A; Marín-Ramos NI; Bergamo F; Schirripa M; Lonardi S; Lenz HJ; Loupakis F; Battaglin F
Drug Saf; 2019 Feb; 42(2):211-233. PubMed ID: 30649748
[TBL] [Abstract][Full Text] [Related]
47. [MET signalling pathway and its therapeutic implications in gastrointestinal cancers].
Zaanan A; Laurent-Puig P; Taieb J
Bull Cancer; 2014 Jan; 101(1):25-30. PubMed ID: 24445683
[TBL] [Abstract][Full Text] [Related]
48. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.
Liang Z; Ding X; Ai J; Kong X; Chen L; Chen L; Luo C; Geng M; Liu H; Chen K; Jiang H
Org Biomol Chem; 2012 Jan; 10(2):421-30. PubMed ID: 22108637
[TBL] [Abstract][Full Text] [Related]
49. Molecular cancer therapy: can our expectation be MET?
Migliore C; Giordano S
Eur J Cancer; 2008 Mar; 44(5):641-51. PubMed ID: 18295476
[TBL] [Abstract][Full Text] [Related]
50. Kinase inhibitors: the road ahead.
Ferguson FM; Gray NS
Nat Rev Drug Discov; 2018 May; 17(5):353-377. PubMed ID: 29545548
[TBL] [Abstract][Full Text] [Related]
51. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
Ma PC; Tretiakova MS; Nallasura V; Jagadeeswaran R; Husain AN; Salgia R
Br J Cancer; 2007 Aug; 97(3):368-77. PubMed ID: 17667909
[TBL] [Abstract][Full Text] [Related]
52. C-MET as a new therapeutic target for the development of novel anticancer drugs.
Cañadas I; Rojo F; Arumí-Uría M; Rovira A; Albanell J; Arriola E
Clin Transl Oncol; 2010 Apr; 12(4):253-60. PubMed ID: 20462834
[TBL] [Abstract][Full Text] [Related]
53. Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB.
Wang P; Zhang L; Hao Q; Zhao G
Mini Rev Med Chem; 2011 Nov; 11(13):1093-107. PubMed ID: 22353219
[TBL] [Abstract][Full Text] [Related]
54. MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside.
Avan A; Maftouh M; Funel N; Ghayour-Mobarhan M; Boggi U; Peters GJ; Giovannetti E
Curr Med Chem; 2014; 21(8):975-89. PubMed ID: 23992325
[TBL] [Abstract][Full Text] [Related]
55. Virtual Screening Guided Design, Synthesis and Bioactivity Study of Benzisoselenazolones (BISAs) on Inhibition of c-Met and Its Downstream Signalling Pathways.
Zhang S; Song Q; Wang X; Wei Z; Yu R; Wang X; Jiang T
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137515
[TBL] [Abstract][Full Text] [Related]
56. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
Liu Y; Jin S; Peng X; Lu D; Zeng L; Sun Y; Ai J; Geng M; Hu Y
Eur J Med Chem; 2016 Jan; 108():322-333. PubMed ID: 26698536
[TBL] [Abstract][Full Text] [Related]
57. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
[TBL] [Abstract][Full Text] [Related]
58. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
59. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
Feng Y; Thiagarajan PS; Ma PC
J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
[TBL] [Abstract][Full Text] [Related]
60. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
Liu X; Newton RC; Scherle PA
Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]